Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

News & Events

CGM and exercise trial

Children with Type 1 Diabetes (aged eight to 12 years) are needed for a new trial into Continuous Glucose Monitoring (CGM) and exercise.

News & Events

Sprint study

Join us in Western Australia's first home-based study looking at the effect of sprinting during exercise in Type 1 Diabetes.

News & Events

Transitioning from paediatric to adult diabetes services

The period of transition between paediatric (child) services and adult-based services is a sensitive one for patients with diabetes.

About us

Find out what the Children's Diabetes Centre is and what research it is conducting.

Pump Comparison tool

Pump Comparison tool . This easy-to-use updated comparison tool is designed to help you pick the right device for your family.

Research

The Brain Basis of Comorbidity in Neurodevelopmental Disorders

This review discusses early brain development and the etiological factors that may give rise to atypical developmental trajectories, along with neuroimaging insights

Research

Small-molecule screen reveals synergy of cell cycle checkpoint kinase inhibitors with DNA-damaging chemotherapies in medulloblastoma

Medulloblastoma (MB) consists of four core molecular subgroups with distinct clinical features and prognoses. Treatment consists of surgery, followed by radiotherapy and cytotoxic chemotherapy. Despite this intensive approach, outcome remains dismal for patients with certain subtypes of MB, namely, MYC-amplified Group 3 and TP53-mutated SHH. Using high-throughput assays, six human MB cell lines were screened against a library of 3208 unique compounds. We identified 45 effective compounds from the screen and found that cell cycle checkpoint kinase (CHK1/2) inhibition synergistically enhanced the cytotoxic activity of clinically used chemotherapeutics cyclophosphamide, cisplatin, and gemcitabine.

Research

Immunogenicity and Immune Memory after a Pneumococcal Polysaccharide Vaccine Booster in a High-Risk Population Primed with Pneumococcal Conjugate Vaccine

PPV is immunogenic in 9-month-old children at high risk of pneumococcal infections and does not affect the capacity to produce protective immune responses

Research

Trial refresh: A case for an adaptive platform trial for pulmonary exacerbations of cystic fibrosis

This review will discuss the necessary steps required for a Bayesian adaptive platform trial to optimize treatment of pulmonary exacerbations of cystic fibrosis